AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
InMed Pharmaceuticals Inc.
Video analysis: INM
All videosNo video analysis for this stock yet. Request one from our team.
News: INM
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.
Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)
InMed Pharmaceuticals (NASDAQ: INM - Get Free Report) and Reviva Pharmaceuticals (NASDAQ: RVPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation. Institutional and Insider Ownership 20.1% of InMed
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
Mentari Therapeutics, a privately held biotechnology enterprise dedicated to preventing migraines, has successfully secured an additional $200 million through a new private placement.
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors.
Artisan Mid Cap Fund Q2 2026 Performance Review
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. InMed also announced that it has filed a registration statement on Form S-4 (the "S-4") with the U.S. Securities and Exchange Commission (the "SEC") containing a preliminary proxy statement/prospectus and management information circular in connection with the proposed merger (as amended, the "Merger") and related transactions contemplated by the Agreement (the Merger together with such related transactions, the "Contemplated Transactions").
